Skip to main content
In this older grp of pts w/ chronic LBP, significant overlaps of deg & inflamm features on spinal imaging of DC, DIS

sheila

2 years 9 months ago
In this older grp of pts w/ chronic LBP, significant overlaps of deg & inflamm features on spinal imaging of DC, DISH & axSpA pts were seen Also, +comorbids: HTN in DC; DM in DISH; smoking in axSpA THM? DC & DISH are also axSpA mimics #ACR23 ABST1862 @Rheumnow @rheumarhyme https://t.co/uNIwRchF1g
HCQ improves complements
A#2327 #ACR23 @RheumNow
Petri @jhrheumatology @andreafava
Pts w/ low complement & low HCQ

Eric Dein

2 years 9 months ago
HCQ improves complements A#2327 #ACR23 @RheumNow Petri @jhrheumatology @andreafava Pts w/ low complement & low HCQ levels In pts who increased HCQ WB level >50 ng/mL, incr in mean C3 (p=0.02) v HCQ that did not incr More nml C4 levels (p=.003) and incr mean C4 (p=.004) on HCQ https://t.co/J7PIuaRTO8
HCQ Discontinuation
A#2343 #ACR23 @RheumNow
42 pts d/c HCQ
19% flared in past yr before d/c
D/c reasons: retina tox 57%

Eric Dein

2 years 9 months ago
HCQ Discontinuation A#2343 #ACR23 @RheumNow 42 pts d/c HCQ 19% flared in past yr before d/c D/c reasons: retina tox 57%, self-dc 17%, other eye issue 12% 26% flare in yr after d/c - strongest ass for flare: mean C3, dsDNA+ at index visit https://t.co/d4TqneS46u
Another day, another bimekizumab (IL17i) study

Across 2 trials, improved PsA specific QOL ("PsAID") metrics

Nice to se

Mike Putman EBRheum

2 years 9 months ago
Another day, another bimekizumab (IL17i) study Across 2 trials, improved PsA specific QOL ("PsAID") metrics Nice to see focus on PROs & I always love a good spidergram @RheumNow #ACR23 Absr2249 https://t.co/dsLXstPzt2
The patients’ voice matters! Watch my interview with @LAlupusLady regarding how she manages #Lupus and her perspective

TheDaoIndex KDAO2011

2 years 9 months ago
The patients’ voice matters! Watch my interview with @LAlupusLady regarding how she manages #Lupus and her perspective about the disease @rheumnow #ACR23 @uptoTate https://t.co/P9KPJQEkRv
All of us need to remind each other to take care of yourself!

Some tips from Dr. Whitney Marvin
- exercise, date night

Robert B Chao, MD

2 years 9 months ago
All of us need to remind each other to take care of yourself! Some tips from Dr. Whitney Marvin - exercise, date night, talking to a friend - take breaks, mindfulness - eating away from computer (as I type this on my desk, next to my lunch) @RheumNow #ACR23 https://t.co/UmmDqXRECN
Will postpartum BME ⏩axSpA-like structural lesions?

Study by Varkas et al show there was no significant dev't of axSp

sheila

2 years 9 months ago
Will postpartum BME ⏩axSpA-like structural lesions? Study by Varkas et al show there was no significant dev't of axSpA-like lesions on MRI in postpartum women 5 yrs after delivery. Postpartum BME likely sec to transient mech stress-induced SI BME #ACR23 ABST1892 @RheumNow https://t.co/KJ3DngmkbI
Always refreshing to hear from another specialist's point of view
Cardiologist @Bweber04 on CVD and rheumatologic diseas

Robert B Chao, MD

2 years 9 months ago
Always refreshing to hear from another specialist's point of view Cardiologist @Bweber04 on CVD and rheumatologic diseases Increased risk of death, MI and HF exacerbation in our pt population Increased all cause mortality @RheumNow #ACR23 https://t.co/yOkPOmxU4N
@Bweber04 on recurrent pericarditis especially some seen in our lupus population

IL-1 inhibition with Rilonacept really

Robert B Chao, MD

2 years 9 months ago
@Bweber04 on recurrent pericarditis especially some seen in our lupus population IL-1 inhibition with Rilonacept really redefining treatment success and altering the typical treatment algorithm @RheumNow #ACR23 https://t.co/Ey1DN8eSXT
Later today at #ACR23 at 4pm
See Ab#2545 on IV secukinumab for AxSpA
Read about it now on @RheumNow:
https://t.co/s9Iinp

Eric Dein

2 years 9 months ago
Later today at #ACR23 at 4pm See Ab#2545 on IV secukinumab for AxSpA Read about it now on @RheumNow: https://t.co/s9IinpVxgR
RheumNow’s expanded coverage of #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by Rheu

Dr. John Cush RheumNow

2 years 9 months ago
RheumNow’s expanded coverage of #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Interesting counterpoint to a tweet from a few days ago re:black box warning for JAKs

No change in utilization rates po

Mike Putman EBRheum

2 years 9 months ago
Interesting counterpoint to a tweet from a few days ago re:black box warning for JAKs No change in utilization rates post black box... maybe people had already baked this into the cake by then? @RheumNow #ACR23 Abstr 2142 https://t.co/K9cWbRSWV6
×